Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 27Recurrence 3Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Neoplasm, Residual 1Myasthenia Gravis 1Cytokine Release Syndrome 1

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × talquetamab × Clear all
NCT07499323 2026-04-08

Talquetamab in Patients With Refractory Generalized Myasthenia Gravis

First Affiliated Hospital of Chongqing Medical University

Phase NA Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡